Clinical Trial for GNX80 in Intermittent Claudication

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

Also called NCT05400395

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05400395
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05400395. Randomized; quadruple masking; primary purpose treatment. Start 2022-09-05 (actual); primary completion 2024-03 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Trial for GNX80 in Intermittent Claudication
Intervention (Drug)
GNX80
Intervention (Drug)
Placebo
Lead sponsor
SK Chemicals Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct05400395
Content hash
5c964a63b890b9cc7e003d4f4c9f2d346ea5ff7008fd584d9afe974bc1684563